Grünes Licht: Novartis supports EU-Zulassung für Kisqali at Brustkrebs in Frühstadium

On November 27, 2024By Pranco

Green Light

Novartis accepts EU-Zulassung für Kisqali at Brustkrebs in Frühstadium

Delivery in September in the US for diesel. The European Union will see this later.

Published at 08:06 Uhr

This Zulassung is a Meilenstein for Brustkrebspatientinnen in the Frühstadion in Europe, the heisst is in a Novartis-Mitteilung.

Image: thomasandreas/Getty Images

You can subscribe and make a profit from the previous function.

BotTalk

Novartis hat voor das Brustkrebsmittel Kisqali von der Europäischen Kommission eine weitere Zulassung erhalten. The Mittel Wurde Für die Behandling von «HR+/HER2-»-Brustkrebs in Frühstadium with a high relapse risk-zugelassen, with Novartis am Mittwoch Mitteilte.

The basis for the research is based on data from the Phase III study “Natalee”. These have been said that Kisqali (Ribociclib) in combination with endocrine therapy (ET), also an antihormone therapy, is a clinical treatment for the patient’s hypersensitivity to endocrin therapy.

This disease is a melenstein for the breast krebs patients in the Frühstadium in Europe, one of the best, which is now a new option for the Verfügung, a relapse risk for a wide patient group in the verringern, with Michael Gnant, professor at the Medizinische Universität Wien, in the Mitteilung zitiert. I’ll be in Kisqali, USA in September for diesel indication suction welding.

An dieser Stelle finden Sie einen ergänzenden externaln Inhalt. Once you set a cookie, cookies from external users are set and external people are added to the external data that you can use to set all cookies and get external direct access.

AWP

Fehler financed?Jetzt reports.

Aktien-Alert

From ABB with its Züblin – see if you have an E-Mail, so keep a new Article zum Unternehmen Ihrer Wahl erscheint.

If you need a service, please sign up or register.